Compare BOC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOC | BWAY |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.8M | 451.2M |
| IPO Year | 2017 | 2019 |
| Metric | BOC | BWAY |
|---|---|---|
| Price | $12.76 | $22.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $25.00 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 153.0K | 132.5K |
| Earning Date | 11-13-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $112,601,970.00 | $49,094,000.00 |
| Revenue This Year | $6.06 | $330.76 |
| Revenue Next Year | $4.04 | $22.24 |
| P/E Ratio | ★ N/A | $73.97 |
| Revenue Growth | 7.22 | ★ 27.08 |
| 52 Week Low | $11.30 | $7.84 |
| 52 Week High | $15.75 | $25.65 |
| Indicator | BOC | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 53.93 |
| Support Level | $11.87 | $22.97 |
| Resistance Level | $12.25 | $25.65 |
| Average True Range (ATR) | 0.25 | 1.30 |
| MACD | 0.07 | -0.28 |
| Stochastic Oscillator | 74.90 | 28.49 |
Boston Omaha Corp is a United States based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. Company generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.